

AB - International Health Care Portfolio

聯博 - 國際健康護理基金

OVERALL MORNINGSTAR RATING $^{\sim}\!\Delta$ ***

Important Information 重要事項

- The Portfolio may invest in European securities where the issuers have their registered office or exercise the predominant part of their economic activities in Europe. A significant deterioration of the European debt crisis could have a significant adverse impact on some of the Portfolio's investments. 本基金可投資於註冊辦事處位於歐洲或主要經濟活動在歐洲進行的發行人所發行的歐洲證券。倘若歐債危機嚴重惡化,可能對本基金的一些投資造成嚴重不利的影響。
- 2 Invest in emerging markets is subject to higher volatility and higher risks (e.g. liquidity risk, currency risk, political risk, regulatory risk and economic risk). 投資於新興市場面對較高的波動性及較高的風險(例如流動性風險、貨幣風險、政治風險、監管風險及經濟風險)。
- 3 Investment in the portfolio may also involve industry/sector risk, currency risk, management risk, Eurozone risk and health care industries risks. The value of the portfolio can be volatile and can go down substantially within a short period of time. It is possible that the entire value of your investment in the portfolio can be lost. り 投資於本基金亦可能涉及行業∕界別風險、貨幣風險、管理風險、歐元區風險及健康護理行業風險。基金價格可反覆波動,並可在一段短時期內顯著下跌。閣下於本基金的投資可能會
- 4 The portfolio is entitled to use financial derivative instruments for hedging and efficient portfolio management purposes which may involve additional risks. In adverse situations, the portfolio's use of derivative instruments may become ineffective in hedging or efficient portfolio management and the portfolio may suffer significant losses 本基金可使用衍生工具達到對沖及有效基金管理的目的,這可能涉及額外風險。在不利情況下,本基金使用的衍生工具未必能夠有效地達到對沖或有效基金管理的目的,且本基金可能 會遭受重大損失。
- Investors should not rely on this document alone to make investment decisions. 投資者不應只依賴本文件而作出投資決定。

The Portfolio seeks capital appreciation through investments on a worldwide basis in equity securities of companies that are engaged in health care and health science industries. The Portfolio invests in a global portfolio of securities of companies selected for their capital appreciation opportunities. Through a bottom-up selection process, the team attempts to determine market leaders with superior research, financial controls and marketing capabilities

本基金透過投資於全球各地經營健康護理及衛生科學行業公司的股票證券,以尋求資本增值。本 基金投資於按其資本增值機會所選出的環球公司證券。投資隊伍透過由下而上的選股程序,設法 找出在研究、財務控制及營銷方面具有卓越能力的市場領導者。

Portfolio Composition^{*} 投資組合配置^{*}

Industry Allocation 行業配置



Country Allocation 國家分佈



- Holdings are expressed as a percentage of total investments and may vary over time. 投資組合配置比重以總投資比重之百分比表示,可能隨時間而改變。
- Calculated from the net assets of the Portfolio. 以基金淨資產計算。
- As a percentage of purchase price for Class A only. 適用於 A 股之費用·以認購價格之百分比計算
- As an annual percentage of average daily Net Asset Value. 以每日平均資產淨值之年度百分比率計費用。

Domicile 註冊地點	Luxembourg 盧森堡
Inception Date 基金成立日	05/07/1995 (Class A – USD) (A 股–美元)
Fiscal Year End 財政年度終結	31 May (5 月 31 日)
Net Assets 淨資產	\$ 742.30 Million 百萬美元
Subscription/ Redemption 認購/贖回	Daily 每日
Base Currency 基準貨幣	USD 美元
Reporting Currencies 其他報價貨幣	EUR 歐元
Initial Sales Charge ¹ 首次認購費 ¹	Up to 最多為 5.00% (Class A 股)
Management Fee ² 管理費 ²	First \$300mn: 1.80% ^α Over \$300mn: 1.75% ^α 首 3 億美元: 1.80% ^α 超過 3 億美元部份: 1.75% ^α (Class A 股)
Management Company Fee ² 管理公司費 ²	0.05%
Total No. Of Holdings 總持股數量	43
Portfolio Management Team 基金管理團隊	Vinay Thapar

For fees applicable to other share classes, please refer to the offering documents for details.

有關其他股份類別的費用詳情,請參閱基金銷售文件。

Top 10 Holdings 十大持股

	Sector 行業	Holding 持股量	
Pfizer	Pharmaceuticals 藥品	6.80%	
UnitedHealth Group	Health Care Providers & Services 健康 護理服務	6.70%	
Roche	Pharmaceuticals 藥品	5.97%	
Medtronic	Health Care Equipment & Supplies 健康 護理設備及產品	4.35%	
Johnson & Johnson	Pharmaceuticals 藥品	4.33%	
AstraZeneca	Pharmaceuticals 藥品	4.32%	
GlaxoSmithKline	Pharmaceuticals 藥品	4.11%	
Biogen	Biotechnology 生物科技	4.06%	
Stryker	Health Care Equipment & Supplies 健康 護理設備及產品	3.82%	
Edwards Lifesciences	Health Care Equipment & Supplies 健康 護理設備及產品	3.72%	
Total 合共		48.18%	

Calendar Year Returns 年度回報%~



Cumulative Total Returns 總累積回報%~

	1 Year (年)	3 Year (年)	5 Year (年)	10 Year (年)	Since Inception 成立迄今
Class A – USD A 股–美元	19.6	47.1	88.2	156.9	473.5

Please refer to Footnote ~ for Inception Date of Class A - USD.

請見附註~有關 A 股 - 美元的成立日。

Source: AllianceBernstein (AB), calculated on an NAV-to-NAV basis, with dividend reinvested, in U.S. Dollars 資料來源:AB·按資產淨值比資產淨值計算·股息用於再投資·以美元計。

Past performance is no guarantee of future results. Total returns, provided by AB, include the change in net asset value and reinvestment of any distributions paid on Portfolio shares for the period shown, but do not reflect sales charges. The information on this page is for information purposes only and should not be construed as an offer to sell, or solicitation of an offer to buy, or a recommendation for the securities of the Portfolio. 過往的業績不保證將來的表現。AB 所提供的總回報包括期內之資產淨值變化及股息或利息之再投資 但是並不反映認購費。本頁資訊僅作參閱之用·不應被視作銷售或誘導讀者購買或推薦本基金之證券。

Δ Overall Morningstar Rating is a copyright of Morningstar, Inc., 2018. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. Morningstar rates mutual funds from 1 to 5 stars based on how well they've performed (after adjusting for risk and accounting for sales charges) in comparison to similar funds. Within each Morningstar Category, the top 10% of funds receive 5 stars and the bottom 10% receive 1 star. Funds are rated for up to three time periods-three-, five-, and 10-years and these ratings are combined to produce an overall rating. Funds with less than three years of history are not rated. Ratings are objective, based entirely on a mathematical evaluation of past performance. They're a useful tool for identifying funds worthy of further research, but shouldn't be considered

Δ Overall Morningstar Rating 是晨星有限公司 2018 版權所有。晨星提供的資料:(1)為晨星的獨有資產;(2)未經許可不得複製或轉載;及(3)晨星未就資料的完整性、準確性及即時性作出任何保證。晨星及其 及びは国際の制度を表現する。 内容供應商對於因使用相關資料而代出的交易決定均不承擔任何責任。過往績效記錄不能保證未來投資結果。 晨星將同類型基金比較・以其表現為基礎(經考慮風險及銷售費用而調整後)、從一到五星評級。於晨星各分類内・表現首百分之十的基金評為五星・而尾百分之十的基金評為一星。基金評級分為三個時段:

三年、五年和十年;評級會結合並產生一個整體評級。 基金成立少於三年並不獲評級。評級是客觀的,完全以歷來表現的數學評價為基礎。 評級為鑑定值得進一步研究的基金的有用工具,不應被視作買入 或贖回基金的信號

~ On 31 August 2006 the Portfolio was formed by the merger of ACM International Health Care Fund into the current Portfolio. Performance prior to 31 August 2006 and noted "Since Inception" is actually ACM International Health Care Fund. The investment objective, policies and strategies of the portfolios are substantially the same. The fees and charges for the portfolios were calculated differently, however, their respective estimated total expense ratios are comparable

~本基金於 2006 年 8 月 31 日由 ACM 國際健康護理基金併入現時的本基金而成。2006 年 8 月 31 日前的基金表現及註明為「成立迄今」的成立日期實際上屬於 ACM 國際健康護理基金。兩基金的投資目標、政策及策略大致相同。兩基金的費用及收費計算方法有別・但兩者的估計總開支比率相若。

Investment in the Fund entails certain risks. Investment returns and principal value of the Fund will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. The Fund is meant as a vehicle for diversification and does not represent a complete investment program. Returns denominated in a currency other than the base currency of the fund may increase or decrease as a result of foreign exchange currency fluctuations. These and other risks are described in the Fund's prospectus. Prospective investors should read the prospectus including risk factors carefully and discuss risk and the fund's fees and charges with their financial adviser to determine if the investment is appropriate for them.

投資於本基金須承擔若干風險。投資於本基金的回報及本金值會有波動,故投資者的股份在贖回時的價值可能高於或低於原來成本。本基金旨在作為分散投資的工具,並非完整投資計劃。以基金基準貨幣以 外的貨幣所計價的回報,可能受外匯波動有所增加或減少。此等風險以及其他風險在本基金認購章程內有說明。準投資者應細閱認購章程及其風險因素,並與其理財顧問商討本基金的風險及各項費用,以確

This information is directed solely at persons in jurisdictions where the funds and relevant share class are registered or who may otherwise lawfully receive it. Before investing, investors should review the fund's full prospectus, together with the fund's Product Key Facts and the most recent financial statements. Copies of these documents, including the latest annual report and, if issued thereafter, the latest semi-annual report,

may be obtained free of charge from www.abfunds.com.hk or by contacting the local distributor in the jurisdictions in which the funds are authorized for distribution. 此信息只針對本基金和相關股份類別已註冊之司法權區內人士或其他方式合法接收之人士。投資前,投資者應審查基金的認購章程全文,連同基金的產品資料概要,以及最近期的財務報表。這些文件的副 本,其中包括最近期的年度報告,以及如果其後頒布者,則為最近期的中期報告,可瀏覽 www.abfunds.com.hk 或聯繫基金獲授權經銷司法權區的當地經銷商免費索取,

The Portfolio is part of AB SICAV I (referred to as "AB"). AB is an open-ended investment company with variable capital (société d'investissement à capital variable) incorporated under the laws of the Grand Duchy of Luxembourg. Prior to 5 February 2016, AB's legal name was ACMBernstein SICAV, its trading name was AllianceBernstein.

本基金為 AB SICAV I(即 "聯博")旗下的一個投資組合。聯博是根據盧森堡大公國法律註冊成立的開放型可變資本投資公司(société d'investissement à capital variable) · 法定名稱為 AB SICAV I 。在 2016 年 2 月 5 日之前 · 聯博的法定名稱為 ACMBernstein SICAV · 營業名稱為 AllianceBernstein。

This document is issued by AllianceBernstein Hong Kong Limited and has not been reviewed by the Securities and Futures Commission.

此文件的發行者為聯博香港有限公司及未經證監會審閱。

©2018 AllianceBernstein L.P. The [A/B] logo is a service mark of AllianceBernstein and AllianceBernstein is a registered trademark used by permission of the owner, AllianceBernstein L.P. ©2018 AllianceBernstein L.P. [A/B] 標誌為 AllianceBernstein 的服務標記·而 AllianceBernstein in AllianceBernstein L.P. (B/B) 標誌為 AllianceBernstein in OhlianceBernstein in OhlianceBernstein

NAV Information (as of 30/09/2018)

資產淨值資料(截至 2018 年 09 月 30 日)

	NAV 基金淨值	Bloomberg	ISIN
Class A – USD A 股–美元	357.97	ALLHCFA:LX	LU0058720904